Objective. , an interleukin-12 (IL-12) cytokine family member, is shown to be a potent immunosuppressive and anti-infl ammatory cytokine. Inducible regulatory T cells (Tregs) produce IL-35 that mediates the immune inhibitory function of Tregs. Growing evidence revealed that upregulation of IL-35 expression may play a critical role in the prevention of autoimmune diseases in various experimental autoimmunity models and vice versa. Hashimoto's thyroiditis (HT) is considered to be a Treg cell-related autoimmune disease with loss of self-tolerance.
Hashimoto's thyroiditis (HT) is the most common cause of the hypothyroidism in the iodine-suffi cient areas of the world. It is a part of the spectrum of autoimmune thyroid diseases (AITDs), in which the thyroid gland is attacked by a variety of cell-and antibody-mediated immune processes (Jacobson and Tomer 2007; Stathatos and Daniels 2012; Cogni and Chiovato 2013; Caturegli et al. 2014 ; Eff raimidis and Wiersinga 2014). Loss of self-tolerance to thyroid antigens is hallmark of HT (Jacobson and Tomer 2007; Cogni and Chiovato 2013) . HT is characterized by the presence of lymphocytic infi ltration in the thyroid, circulating thyroid autoantibodies, and thyroid cell apoptosis leading to follicular destruction rather than thyroid stimulation and thyroid cell hyperplasia (Jacobson and Tomer 2007; Stathatos and Daniels 2012; Cogni and Chiovato 2013; Caturegli et al. 2014; Eff raimidis and Wiersinga 2014) .
Regulatory T cells (Tregs) are a subset of CD4 + T cells that are characterized by expression of the transcription factor Foxp3 and high surface expression of CD25 (Fehervari and Sakaguchi 2004; AitOufella et al. 2006) . Tregs are responsible for maintenance of the immune tolerance through active immune suppression and regulation of immune response (Shevach 2009; Pellerin et al. 2014) . Reduction of the Tregs number is thought to play a role in the initiation and development of autoimmune process in thyroid disorders (Bossowski et al. 2013) . , an IL-12 cytokine family member, is a crucial mediator which promotes CD4+CD25+ T cell proliferation, inhibits CD8+ T cell function, and suppresses full-blown infl ammation (Collison and Vignali 2008; Collison et al. 2007; 2009; . Secretion of IL-35 has only been detected in non-stimulated mouse Tregs (Collison et al. 2007) and stimulated human Tregs (Chaturvedi et al. 2011) . IL-35 exerts clear immunosuppressive/anti-infl ammatory activities in various autoimmunity models such as experimental colitis (Collison et al. 2007 , Wirtz et al. 2011 , collagen-induced arthritis (Niedbala et al. 2007 ), autoimmune encephalomyelitis (Collison et al. 2010) , autoimmune diabetes (Bettini et al. 2012) , and allergic airway disease (Whitehead et al. 2012) . Th e role of IL-35 in autoimmune hypothyroidism, especially HT, is intriguing topics.
Exact mechanism of HT has remained still obscure. Th e aim of this study was to explore whether circulating levels of IL-35 is related to HT and any components of HT.
Subjects and Methods
Subjects. One hundred-twenty-eight newly diagnosed hypothyroid HT patients (56 overt, 72 subclinical hypothyroid) were enrolled in the study. Diagnosis of HT was based on three main fi ndings: the presence of goiter, typical ultrasonography, and presence of serum antibodies against thyroid antigens (mainly to thyroperoxidase and thyroglobulin). Subclinical hypothyroidism was defi ned as elevated serum concentrations of thyroid stimulating hormone (TSH=4.5-10 μIU/ml), normal serum concentrations of free thyroxine (FT4) and triiodothyronine (FT3), whereas overt hypothyroidism was defi ned as low free thyroid hormone levels (FT4 or FT3) and TSH ≥4.5 μIU/ml. Subjects were excluded if she/he had a history of and current nodular-multinodular goiter, chronic respiratory diseases, smoking, neuromuscular disease, narcolepsy, transient ischemic attack, malignancy, renal dysfunction, chronic heart failure, autoimmune hepatitis, type 1 diabetes (T1DM), multiple sclerosis (MS), rheumatoid arthritis, alcoholic abuse or sedative drug user, current pregnancy, other endocrinological diseases, and recent infection.
Th e control group comprised of apparently healthy individuals, who were not complaining from any chronic medical diseases with normal clinical examinations, no history of thyroid diseases or any chronic illness may interfere with our results.
Informed consent was obtained in all cases, and the study was approved by the local ethics committee (IRB Number: 9950669/351).
All patients with HT were treated aft er the fi rst examination with oral levothyroxine. Anthropometric measurements, serum lipid and IL-35 levels, were measured at the time of diagnosis. Measurements of anthropometric parameters were performed for the study subjects before breakfast when wearing light clothing and no shoes. Th e heights and weights were measured. Th e body mass index (BMI) was calculated as the weight/height 2 (kg/m 2 ). Biochemical analysis. Venous blood samples were collected from the participants by venipuncture after a 12 h-overnight fasting. Serum total cholesterol (TC), triglyceride, and high-density lipoprotein cholesterol (HDL-C) were measured with Cobas 6000 analyzer series (Roche diagnostics, Mannheim, Germany). Serum low-density lipoprotein cholesterol (LDL-C) was calculated using the Friedewald formula: LDL-C=TC-HDL-C-(triglyceride/5.0). Serum hsCRP was analyzed using the same automated chemistry analyzer, and the reference values applied were 0 to 3.0 mg/l. Serum TSH, FT4, FT3, anti-thyroid peroxidase antibodies (TPOAb) and anti-thyroglobulin antibodies (TgAb) levels were evaluated using Cobas e601 (Roche diagnostics, Mannheim, Germany) with electrochemiluminescence immunoassay (ECLIA) method. Normal ranges in our laboratory are as follows: TSH=0.27-4.20 μIU/ml, FT4=0.93-1.70 ng/dl, FT3=2.0-4.40 pg/ml, TPOAb <35.0 IU/ml, TgAb <115.0 IU/ml.
Enzyme-linked immunoassay (ELISA). Blood samples were centrifuged for 15 min at 1000×g and separated sera were stored at -80 °C. Serum levels of IL-35 were determined using commercially available ELISA kit (Cat. No. CSB-E13126h, Cusabio, INC, Wuhan, P.R. China). Th e intra-and inter-assay coeffi cients of variation were 6% and 8%, respectively. Sensitivity was 15.6 pg/ml. All samples were analyzed in duplicates.
Ultrasound (US) evaluation of thyroid gland was performed with an HD15 PureWave Ultrasound System (Philips Medical Systems, Bothell, WA, USA) with using a 5-cm, 5-12 MHz linear transducer by two blinded radiologists experienced in thyroid imaging. Images were obtained in the transverse and longitudinal planes. Th yroid volume for each lobe was calculated using the mean of the elliptical shape volume formula (π/6×length×width×depth). Th e sum of two thyroid lobe volumes gave the total thyroid volume (Collison et al. 2009 ). Volume of the isthmus was not included in this calculation. Defi nition of Goiter was based on Gutekunst's criteria. Gutekunst reference values for adults (>18 cm 3 in women and >25 cm 3 in men) were used (Gutekunst et al. 1986; Gutekunst and Martin-Teichert 1993) . US features of diff use thyroiditis (DT) were defi ned using the generally accepted standards of diff use parenchymal hypoechogenicity or a heterogeneous echogenic pattern of the thyroid gland.
Statistical analysis. Th e normality of parameters was examined by using Kolmogorov-Smirnov test. Continuous data were expressed as means ± SD, median (range) and the diff erences were analyzed with one-way analysis of variance (ANOVA, normal distribution) or Kruskal-Wallis test with MannWhitney U test (abnormal distribution or unequal variances). If a signifi cant diff erence was found aft er ANOVA among groups, we performed paired comparisons with the Tukey post hoc test. Categorical variables were presented by frequency counts, and the diff erences were tested using the chi-square test or Fisher exact test. Associations of IL-35 with laboratory markers, clinical evaluations and thyroid volume were analyzed by use of Spearman rank order correlations. IBM SPSS Statistics version 20 was used for the statistical analyses and p<0.05 was considered statistically signifi cant. 
Results
Th e subjects were divided into three groups based on the thyroid hormone profi le:
Group 1 (n=56) comprised of newly diagnosed overt hypothyroidism due to HT; Group 2 (n=72) comprised of newly diagnosed subclinical hypothyroidism due to HT; Group 3 (n=38) comprised of healthy euthyroid individuals without past or present thyroid diseases and any disease.
Characteristics of the groups are shown in Table 1 (Figure 1 ).
Correlation analysis revealed that serum levels of IL-35 inversely correlated with TSH (rs=-0.396, p<0.001) (Figure 2 ) and TPOAb (rs=-0.571, p<0.001) (Figure 3 ) in all groups (Group 1 + Group 2 + Group 3). However, there was no signifi cant correlation of IL-35 levels with free thyroid hormones, TgAb, lipid parameters, CRP and thyroid volume (p>0.05) in all groups. We found that the serum levels of IL-35 were negatively correlated with TSH (rs=-0.264, p=0.003) (Figure 4 ) and TPOAb (rs=-0.735, p<0.001) ( Figure 5 ) in patients with HT (Group 1 + Group 2). However, no signifi cant correlation was found between IL-35 levels and other parameters (free thyroid hormones, TgAb, lipid parameters, CRP and thyroid volume) (p>0.05) in patients with HT.
Discussion
In the present study, serum IL-35 levels were low in patients with newly diagnosed HT. Furthermore, serum IL-35 levels were inversely associated with TSH and TPOAb. To our best knowledge, this is the fi rst study, in which IL-35 levels were evaluated in patients with new-diagnosed HT. IL-35, mainly synthesized by Tregs, has an important role in the pathogenesis of several infl ammatory and autoimmune conditions (Collison et al. 2007; Niedbala et al. 2007; Collison et al. 2010 , Wirtz et al. 2011 Bettini et al. 2012; Whitehead et al. 2012) . IL-35 promotes the immune inhibitory function and proliferation of Tregs. It contributes to development of autoimmune thyroiditis by causing loss of immune tolerance depending on the decrease in number of Tregs and impairment of their function (Shevach 2009; Bossowski et al. 2013 ; Pel- ). In the current study, besides fi nding low IL-35 levels in the hypothyroidism group, IL-35 levels in the overt hypothyroidism group were found lower than the subclinical group. Th e relationship between other anti-infl ammatory cytokines (IL-4, TGF-beta, IL-10) that have similar properties as IL-35 and autoimmune hypothyroidism has been demonstrated. Reduced TGF-beta levels have been associated with HT (Akinci et al. 2008; Vural et al. 2009 ), whereas increased levels of TGF-beta and IL-10 have been showed to suppress experimental autoimmune thyroiditis (Gangi et al. 2005; Wang et al. 2009; Yu et al. 2010) . Th ese studies were consistent with our results, which suggested that decreased levels of IL-35 were related to HT.
Th e decreased IL-35 levels may contribute to both development of autoimmune thyroiditis and gradual intensifi cation of hypothyroidism by leading to impairment in Treg cell numbers and functions. Besides, IL-35 levels might decrease impairment in Treg cell functions because of impairment in Treg cell functions and decrease in number of Tregs. Th e most important mechanism that might explain the physiopathological relation between IL-35 and autoimmune hypothyroidism is the reciprocal interactions between IL-35 and Tregs.
Th e characteristics of thyroid cell destruction for autoimmune thyroiditis can be seen as the consequence of inappropriate expression of Fas or TRAIL death pathway molecules and down-regulation of the apoptosis controlling protein Bcl-2 (Giordano et al. 2001; Stojanovic et al. 2009 ). Recently, one study has shown that IL-35 inhibited apoptosis in paraffi nembedded human pancreas cancer cell lines via an increase in Bcl-2 and a decrease in TRAILR1 (Nicholl et al. 2014) . Similarly, we assumed that decreased levels of IL-35 could induce apoptosis that may also be involved in the pathogenesis of HT.
Th e presence of an inverse relation between IL-35 level and TPOAb is one of the most important fi ndings, which have been demonstrated in the current study. Recombinant IL-35 can lead to decreased antibody titers in the mouse model of collagen-induced arthritis (Kochetkova et al. 2010) . Decreased levels of IL-35 can mediate the production of antibodies (especially TPOAb) through blocking T cell regulatory functions (Olson et al. 2013) . Th e results of this study are consistent with our fi ndings. We have demonstrated that as the level of IL-35 increases, TPOAb decreases and as IL-35 level decreases, TPOAb increases. TPOAb and TgAb, polyclonal antibodies of the immunoglobulin G (IgG) class, are found in high levels in patients with HT (Olson et al. 2013) . Th ese antibodies can cause the thyroid destruction by complement activation and antibody dependent cell cytotoxicity, but their role in Hashimoto disease still is unclear (Chardes et al. 2002; Lewis et al. 2013) . Th e increased TPOAb depending on the decrease in IL-35 levels might be one of the mechanisms that contribute to development of HT. Recent study has shown that recombinant IL-35 suppressed the proliferation of primary mouse B cells (Wang et al. 2014 ). In addition, IL-35 suppressed autoimmune disease via induction of regulatory B cells. We presumed that decreased IL-35 level could lead to stimulate the proliferation of TPOAb-produced B cells.
Th e present study has several limitations. Firstly, we did not establish causal relationship between IL-35 and HT because of cross-sectional design. Secondly, we did not measure the proportion of Tregs in the circulation and thyroid tissue. Th irdly, apoptotic markers (Bcl-2, Fas, TRAIL) were not used to assess the apoptotic activity in the circulation and also thyroid tissue. Fourthly, this study has a relative small sample size.
In conclusion, decreased levels of IL-35 were associated with autoimmune hypothyroidism and its severity. We suggest that IL-35 exerts a protective eff ect against autodestruction of thyroid tissue. Th is study was to ascertain whether there could be a role for IL-35 in human autoimmune thyroid disease. We hypothesize that in this condition the role of IL-35 might be directed to the stimulation of Treg cell proliferation and antibody production rather than to the suppression of the infl ammation. Further studies are needed to elucidate a link between IL-35 and autoimmune hypothyroidism.
